We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Electronic Nose Sniffs Out Prostate Cancer

By LabMedica International staff writers
Posted on 19 May 2014
Print article
Image: The ChemPro100 Handheld Chemical Detector (eNose) (Photo courtesy of Environics).
Image: The ChemPro100 Handheld Chemical Detector (eNose) (Photo courtesy of Environics).
Soon it may be possible to make a rapid, early diagnosis of prostate cancer using a noninvasive electronic nose that sniffs a urine sample.

Prostate cancer is the second most common malignancy in men and one of the leading causes of death from cancer and it is difficult to diagnose and make reliable prognoses about the disease because it does not appear consistently in prostate tissue.

Scientists at the University of Tampere (Finland) tested 50 patients with confirmed prostate cancer and 24 samples from 15 patients with benign prostatic hyperplasia. Fifteen patients provided urine preoperatively and nine patients provided samples three months postoperatively and all patients were scheduled to undergo robotic assisted laparoscopic radical prostatectomy or transurethral resection of the prostate.

The electronic nose or eNose used in the study was a commercially available model ChemPro100 (Environics Inc.; Mikkeli, Finland) based on the ion mobility spectrometry principle. The device contains an ion mobility cell that consists of eight electrode strips producing two-channel output and a metal oxide based semiconductor cell. Together these sensors produce 18-channel measurement data. The sensors do not specify molecules, but produce a characteristic smell print of the sample.

The team found that the eNose, which analyzed molecules in the urine headspace, was able to discriminate prostate cancer from benign prostatic hyperplasia with a sensitivity of 78% and a specificity of 67%, on a par with the prostate specific antigen (PSA) tests. Niku Oksala, MD, PhD, DSc, the senior author of the study said, “PSA is known to correlate positively with prostate volume, which is a potential source of diagnostic error when comparing prostate cancer with benign disease. According to our current analysis, prostate volume did not affect the eNose results, potentially indicating high specificity of our sensor array to cancer.” The study was published online on February 25, 2014, in the Journal of Urology.

Related Links:

University of Tampere
Environics Inc.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.